

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(21) (A1) 2,124,161
(22) 1994/05/24
(43) 1994/11/26

(51) INTL.CL. ⁵ A61K-035/62; A61K-035/16; A61K-037/64

(19) (CA) **APPLICATION FOR CANADIAN PATENT** (12)

(54) Pharmaceuticals for Treating Sepsis and Septic Shock

(72) Dickneite, Gerhard - Germany (Federal Republic of) ;
Bosslet, Klaus - Germany (Federal Republic of) ;

(71) Behringwerke Aktiengesellschaft - Germany (Federal
Republic of) ;

(30) (DE) P 43 17 282.2 1993/05/25

(57) 10 Claims

5,091,4/74

Notice: This application is as filed and may therefore contain an
incomplete specification.



2124161

BEHRINGWERKE AKTIENGESELLSCHAFT HOE 93/B 007 - Ma 973
Auslandstext

Abstract of the Disclosure

Pharmaceuticals for treating sepsis and septic shock

The invention relates to a two-component system for the treatment and prophylaxis of sepsis and of septic shock, where the components are intended to act in combination with each other, to a pharmaceutical and a packaging unit containing both the components, and to a process for their preparation.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A commercially prepared two-component system for the
treatment and prophylaxis of sepsis and of septic
shock, where the components are intended to act in
combination with each other, and where one component
is a thrombin inhibitor and the second a substance
which influences the formation, the liberation, the
plasma and tissue levels, and the receptor binding
of cytokines, or is an inhibitor of complement or of
the kallikrein/kinin system.
2. The two-component system as claimed in claim 1,
wherein the components are contained in a pharmaceu-
tical.
3. The two-component system as claimed in claim 1,
wherein the components are contained in a packaging
unit.
4. The two-component system as claimed in claim 1,
wherein the thrombin inhibitor is an antithrombin
III obtained from human plasma or prepared recombi-
nantly.
5. The two-component system as claimed in claim 1,
wherein the thrombin inhibitor is the natural hiru-
din isolated from leaches or is a recombinantly
prepared hirudin, or a mutant of hirudin, or a
synthetic thrombin-inhibiting substance.
6. The two-component system as claimed in claim 1,
wherein the second component is a recombinantly
prepared, soluble, interleukin I receptor or
receptor antagonist, or its Fc-fusion protein, a
recombinantly prepared, soluble, TNF receptor or
receptor antagonist, or its Fc-fusion protein, or
recombinantly prepared interleukin 10, an inhibitor
of complement, or a C1 esterase inhibitor.

7. The two-component system as claimed in claim 1, wherein the second component is an inhibitor of the kallikrein/kinin system.
- 5 8. The two-component system as claimed in claim 5, wherein the second component is natural antagosan isolated from mammalian tissue, or is recombinantly prepared antagosan.
- 10 9. A process for preparing a two-component system for the treatment and prophylaxis of sepsis and septic shock, where the components are intended to act in combination with each other, and where the one component is a thrombin inhibitor and the second a cytokine antagonist, or an inhibitor of bradykinin or complement, wherein the components are brought
15 into a suitable administration form for use in humans.
- 20 10. The use of a thrombin inhibitor and of a cytokine antagonist, or inhibitor of bradykinin or complement, in a process for preparing a pharmaceutical for the treatment and prophylaxis of sepsis and of septic shock.

BEHRINGWERKE AKTIENGESELLSCHAFT HOE 93/B 007 - Ma 973
Auslandstext

Pharmaceuticals for treating sepsis and septic shock

The invention relates to a two-component system for the treatment and prophylaxis of sepsis and septic shock, where the components are intended to act in combination
5 with each other, to a pharmaceutical and to a packaging unit containing both components, and to a process for their preparation.

Despite the advances which have been made in antibiotic therapy, bacterial sepsis is a central problem in intensive care, and mortality in septic shock is, at 50-70%,
10 still unacceptably high.

It is particularly Gram-negative bacteria which have been demonstrated in patients suffering from sepsis; potential sources of infection are the gastrointestinal tract, the
15 deferent urinary tracts and the respiratory tract, and also infected wounds and burns.

Following liberation of endotoxins (lipopolysaccharide, LPS) from the cell walls of Gram-negative bacteria, the LPS binds to the lipopolysaccharide-binding protein
20 (LPB), and the LPS/LPB complex binds to macrophages via the CD14 receptor. The macrophages which have been stimulated in this way secrete cytokines such as $TNF\alpha$, interleukin 1 and interleukin 6, inter alia. Granulocytes are activated by these mediators, and the endothelium is
25 converted from an anticoagulatory condition into a procoagulatory condition. As a result of the expression of thromboplastin, the extrinsic pathway of coagulation is activated by the formation of a factor VII/thromboplastin complex. This results in activation of the prothrom-
30 binase complex and consequent conversion of inactive prothrombin into enzymatically active thrombin (factor IIa). The cleavage of fibrinogen into fibrin results in the formation of microthrombi (disseminated intravascular coagulopathy, DIC) in the terminal vascular bed. The

decreased blood flow through the bed leads to a deficiency in oxygen supply and, as a consequence, to organ dysfunction (multiple organ failure). On the other hand, LPS can activate factor XII (Hagemann factor) directly by
5 contact activation of the intrinsic coagulation system, and thereby also activate the kallikrein/kinin system and the complement system. The formation of bradykinin causes a fall in blood pressure, and thereby also contributes to the development of septic shock.

10 It is known, for the purpose of sepsis therapy, to employ antibodies against LPS, as well as antibodies, antagonists or soluble receptors against TNF or interleukin 1.

The formation of microthrombi can be suppressed by inactivating thrombin, which is the central protease of
15 the coagulation system.

Antithrombin III is the physiological inhibitor of thrombin, and antithrombin III protein, having a molecular weight of 58 kD, can be isolated from human plasma. Antithrombin III reacts with thrombin in a stoichiometric
20 ratio, the rate of the reaction being greatly increased by sulfated polysaccharides, especially heparin.

A marked drop in the plasma level of active antithrombin III is observed in sepsis and in septic shock, suggesting, on the one hand, increased consumption (formation of
25 a thrombin-antithrombin complex) and, on the other, proteolytic degradation by serine proteases, especially by elastase, which is secreted from polymorphonuclear granulocytes.

It is known that antithrombin III replacement can be
30 employed in sepsis (B. Blauhut et al., Thromb. Res. 39, 81-89, 1985).

Hirudin represents another, highly specific, inhibitor of thrombin. Hirudin has also been demonstrated to possess

activity in experimental sepsis (H. Hoffmann et al., Am. Rev. Respir. Dis. 142, 782-788, 1990).

It was found that both the compounds reduced the mortality rate due to sepsis and prolonged survival time.

- 5 It has now been found, surprisingly, that the antithrombotic therapy of sepsis can be improved by combining it with substances which do not act on the coagulation system, and that this combination leads to a further reduction in mortality in sepsis and in septic shock.
- 10 Examples of suitable thrombin inhibitors are antithrombin III (AT III) prepared from human plasma or recombinantly, and mutants thereof possessing thrombin-inhibiting activity, natural or recombinantly prepared hirudin, and mutants of hirudin possessing thrombin-inhibiting
- 15 activity, or synthetic thrombin inhibitors, that is chemically prepared substances which are notable for their thrombin-inhibiting effects.

- Those compounds which are suitable for combining with an antithrombotic principle are substances which influence
- 20 the formation, the liberation, the plasma and tissue levels and the receptor binding of cytokines, and, in addition, inhibitors of complement and of the kallikrein/kinin system.

- Suitable substances are inhibitors, antagonists or
- 25 soluble receptors of cytokines or antagonists of cytokine receptors, preferably of the cytokines TNF (tumor necrosis factor) and IL-1, or are the fusion proteins of these substances with an Fc moiety of an antibody.

- Examples of suitable cytokine-^{inhibitors} and receptors or antago-
- 30 nists of cytokines are substances which suppress the biological activity of interleukin 1, for example recombinantly prepared soluble IL-1 receptor, recombinantly prepared IL-1 receptor, or an Fc-fusion protein which

contains IL-1 receptor, antagonists of IL-1, i.e. IL-1-like polypeptides which bind to the receptor which do not trigger any signal, substances which suppress the biological activity of tumor necrosis factor (TNF), for example recombinantly prepared soluble TNF receptor, recombinantly prepared TNF receptor or an Fc-fusion protein which contains TNF receptor, antagonists of TNF, i.e. TNF-like polypeptides which bind to the receptor but do not trigger any signal, or recombinantly prepared interleukin 10, or its mutants, which bind to the IL-10 receptor and trigger a signal at that site. Examples of suitable inhibitors of complement or kallikrein are C1 esterase inhibitor (C1INH), purified from human plasma or prepared recombinantly, and its mutants possessing enzyme-inhibiting activity, synthetic complement inhibitors, that is chemically prepared substances which are notable for their complement-inhibiting effect, natural or recombinantly prepared aprotinin, or its kallikrein-inhibiting mutants, or synthetic kallikrein inhibitors, that is chemically prepared substances which are notable for their kallikrein-inhibiting effect.

Combinations of antithrombin III (for example Kybernin^a, Behringwerke AG) or rec. hirudin (Behringwerke AG) with C1 esterase inhibitor (for example Berinert^a, Behringwerke AG) are particularly preferred.

Dosages: AT III	5 - 1000 U/kg
rec. hirudin	0.1 - 20 mg/kg
C1INH	5 - 1000 U/kg

The following examples explain the invention in more detail:

Example 1

Female CD rats were treated with a lethal dose of endotoxin (50 mg/kg, i.v.). Three groups were formed which were infused intravenously (1 ml/h) for 5 hours,

beginning 15 minutes prior to the administration of LPS. Group 1 received physiological sodium chloride solution, group 2 received 0.17 mg/kg \times h recombinant hirudin, group 3 received the combination therapy of 0.17 mg/kg \times h recombinant hirudin and 100 units/kg \times h C1 esterase inhibitor. Table 1 shows that, while rec. hirudin elicits clear prolongation of the survival rate in comparison with the control, the combination therapy using C1 esterase inhibitor was, surprisingly, clearly superior to the therapy using the antithrombotic on its own.

Table 1

		Mortality (% dead)	
		6 h	10 h
15	-----		
	1. Control (n = 8)	50	88
	2. rec. hirudin, 0.17 mg/kg \times h (n = 9)	0	66
20	3. rec. hirudin, 0.17 mg/kg \times h + C1 inhibitor, 100 U/kg \times h (n = 10)	0	20

	Significancies: 1 -> 2 p < 0.01	1 -> 3 p < 0.01	
25	1 -> 3 p < 0.01	2 -> 3 p < 0.05	

Example 2

Two groups were formed using the same animal model as in Example 1: the first group received an infusion of 37.5 U/kg \times h of the thrombin inhibitor antithrombin III, isolated from human plasma, and the second group additionally received 125 U/kg \times h C1 esterase inhibitor. Table 2 shows that the combination therapy using antithrombin III and C1INH was superior to the monotherapy

using the antithrombotic on its own.

Table 2

	Mortality after 8 h (dead/total)
5 -----	
1. AT III 37.5 U/kg x h	19/30
2. AT III, 37.5 U/kg x h + C1INH, 125 U/kg x h	11/30
10 -----	
Significance:	1 -> 2 p < 0.05

Consequently, it can be demonstrated that antithrombotic therapy using antithrombin III and hirudin can be combined with other principles for the prophylaxis and therapy of sepsis and of septic shock.